tbuckley/cabot-search huggingface dataset:
Atopic dermatitis (eczema) in <scp>US</scp> female nurses: lifestyle risk factors and atopic comorbidities
Authors: A.M. Drucker, W.‐Q. Li, L. Lin, E. Cho, T. Li, C.A. Camargo, A.A. Qureshi
Journal: British Journal of Dermatology (2015)

Journal Article Atopic dermatitis (eczema) in US female nurses: lifestyle risk factors and atopic comorbidities Get access A.M. Drucker, A.M. Drucker Division of Dermatology University Health Network Toronto ON CanadaDepartment of Dermatology Warren Alpert Medical School Providence RI U.S.A Search for other works by this author on: Oxford Academic Google Scholar W.‐Q. Li, W.‐Q. Li Department of Dermatology Warren Alpert Medical School Providence RI U.S.ADepartment of Epidemiology, School of Public Health Brown University Providence RI U.S.A Search for other works by this author on: Oxford Academic Google Scholar L. Lin, L. Lin Department of Dermatology Warren Alpert Medical School Providence RI U.S.A Search for other works by this author on: Oxford Academic Google Scholar E. Cho, E. Cho Department of Dermatology Warren Alpert Medical School Providence RI U.S.ADepartment of Epidemiology, School of Public Health Brown University Providence RI U.S.AChanning Division of Network Medicine Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA U.S.A Search for other works by this author on: Oxford Academic Google Scholar T. Li, T. Li Channing Division of Network Medicine Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA U.S.A Search for other works by this author on: Oxford Academic Google Scholar C.A. Camargo, Jr, C.A. Camargo, Jr Channing Division of Network Medicine Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA U.S.ADepartment of Emergency Medicine Massachusetts General Hospital and Harvard Medical School Boston MA U.S.ADepartment of Epidemiology Harvard T.H. Chan School of Public Health Boston MA U.S.A Search for other works by this author on: Oxford Academic Google Scholar A.A. Qureshi A.A. Qureshi Department of Dermatology Warren Alpert Medical School Providence RI U.S.ADepartment of Epidemiology, School of Public Health Brown University Providence RI U.S.AChanning Division of Network Medicine Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA U.S.ADepartment of Dermatology Rhode Island Hospital Providence RI U.S.A Correspondence: Abrar A. Qureshi. E‐mail: abrar_qureshi@brown.edu Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 174, Issue 6, 1 June 2016, Pages 1395–1397, https://doi.org/10.1111/bjd.14373 Published: 01 June 2016
The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities)
Authors: Petro Gerych, Roman Yatsyshyn
Journal: European Respiratory Journal (2014)

Background. We studed the effectiveness and safety of the roflumilast for patients with aggravated COPD, either uncomplicated or complicated by ischemic heart disease (IHD) manifested as stable exertional angina; the analysis is based on clinical symptomatology, the external respiratory function and cell-mediated immune parameters.

Methods. The study involved 191 patients with a stage III COPD. 72 patients (23.03%) were diagnosed with comorbid IHD as stable angina (functional class III). The complex therapy includes roflumilast 500 mg during 6 monthes. Lymphocyte subpopulations were examined by indirect immunofluorescence method. The following monoclonal antibodies were used: CD3+, CD4+, CD8+, CD16+, CD22+.

Result. The complex therapy resulted in an increase in the total number of T-lymphocytes as well as of separate populations. A rise in CD4+ lymphocytes to 1.22-2.54% led to the normalization of the immune-regulatory index. 76.0% of stage III COPD patients showed a tendency towards cell immunity improvement. The normalization of immunogram parameters manifested itself in a rise in the number of T-general lymphocytes as well as their separate subpopulations CD4+ and CD16+ lymphocytes (p<0.05 for both parameters).

Conclusion. The use of roflumilast in complex treatment for both uncomplicated COPD and COPD complicated by IHD reduces clinical symptoms, improves cell-mediated immune parameters, stabilizes the external respiratory function, provides better treatment results.

References:

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Last updated 2011.
Abstract 4644: Curcumin C3 ® prevents ultraviolet B radiation-induced acute damage in JB6 keratinocytes and mouse skin via FGF-2/mTOR/NF-KB pathway
Authors: Alok R. Khandelwal, Arun Anandharaj, Ekshyyan Oleksandr, Tara Moore-Medlin, Abreo Fleurette, Cherie-Ann O. Nathan
Journal: Cancer Research (2015)

Abstract Background and Significance: Aggressive Cutaneous Squamous cell carcinoma (CSCC) of the face has become the second most common type of skin cancer in the USA due to ultraviolet B (UVB) exposure in tanning booths and sun exposure of our military personnel. UVB is a carcinogen and our previous studies established oral administration of Curcumin C3 complex (C3), a standardized preparation of three curcumonoids - Curcumin (76.07%), Demethoxycurcumin (20.28%) and Bisdemethoxycurcumin (3.63%), delayed UVB-induced tumor onset and multiplicity, but not tumor progression. Accordingly, we sort to determine the preventative efficacy of C3® against UVB-induced photodamage in promotion sensitive JB6 skin keratinocytes and SKH-1 hairless mouse epidermis on the early neoplastic events in the development of UVB-induced skin carcinogenesis. Methods: SKH-1 mice were either administered vehicle or C3 (100mg/kg/b.w) complex orally for 14 days followed by a single exposure to UVB radiation (180mj/cm2). Mice were euthanized 24 hours after UVB exposure and skin tissues and serum were collected. For in vitro studies, promoter-sensitive JB6 mouse epithelial cells were pre-treated with C3® for 2 h and the effects on UVB-induced early molecular signaling events were assessed. Results: C3® attenuated UVB-induced epidermal hyperplasia and significantly decreased epidermal and plasma levels of fibroblast growth factor-2 (FGF-2); an important mitogen implicated in proliferation and differentiation of skin keratinocytes. In vitro, C3®blocked UVB-dependent FGF-2 induction and proliferation of cultured keratinocytes via down regulation of nuclear factor kappa B (NF-KB) and Mammalian target of rapamycin (mTOR) signaling pathways. Conclusion: Our findings suggest C3® has the ability to protect mice from UVB-induced acute damage. Further the photo-preventive effects of C3® are mediated, at least in part, via modulation of FGF-2/mTOR/NF-KB signaling. Citation Format: Alok R. Khandelwal, Arun Anandharaj, Ekshyyan Oleksandr, Tara Moore-Medlin, Abreo Fleurette, Cherie-Ann O. Nathan. Curcumin C3 ® prevents ultraviolet B radiation-induced acute damage in JB6 keratinocytes and mouse skin via FGF-2/mTOR/NF-KB pathway. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4644. doi:10.1158/1538-7445.AM2015-4644
Sidecut radius and the mechanics of turning—equipment designed to reduce risk of severe traumatic knee injuries in alpine giant slalom ski racing
Authors: Jörg Spörri, Josef Kröll, Matthias Gilgien, Erich Müller
Journal: British Journal of Sports Medicine (2015)

Background There is limited empirical knowledge about the effect of ski geometry, particularly in the context of injury prevention in alpine ski racing. We investigated the effect of sidecut radius on biomechanical variables related to the mechanics of turning. Methods During a field experiment, six European Cup level athletes skied on three different pairs of giant slalom (GS) skis varying in sidecut radii (30 m, 35 m and 40 m). Using a video-based three-dimensional (3D) kinematic system, a 22-point body segment model of the athletes was reconstructed in 3D, and the variables ground reaction force, centre of mass (COM) speed, COM turn radius, ski turn radius, edge angle, fore/aft position and skid angle were calculated. Results While steering out of the fall line after gate passage, ground reaction force significantly differed between the 30 m and 40 m skis and between the 35 m and 40 m skis. These differences were mainly explainable by larger COM turn radii when skiing on the 40 m ski. During the same turn phase, significant differences in ski turn radius also were found, but there were no differences in edge angle, fore/aft position and skid angle. Summary The sidecut-induced reduction in ground reaction force and the sidecut-induced increase in centre of mass and ski turn radius observed in this study provides indirect evidence of reduced self-steering of the ski. Self-steering plays a central role in the mechanism of anterior cruciate ligament rupture in alpine ski racing.
A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors.
Authors: M. E. Scheulen, K. B. Mross, H. Richly, B. Nokay, A. Frost, D. Scharr, K. Lee, O. Saunders, J. Hilbert, O. Fietz
Journal: Journal of Clinical Oncology (2010)

e13065 Background: BI 811283 has demonstrated potent antitumor activity in cancer models at well-tolerated doses, with hallmarks of Aurora B inhibition. Methods: Patients with advanced, nonresectable and/or metastatic solid tumors were randomized to two treatment schedules (4-week and 3-week) in a bicentric phase I dose-escalation study. The primary outcome measure was to determine the MTD of each treatment schedule; results for the q3w schedule are reported separately. In the 4-week treatment schedule, patients received BI 811283 as a 24 h i.v. infusion on days 1 and 15 of each treatment cycle (q2w). To determine the MTD, a modified 3+3 trial design with de-escalation was conducted. After determination of the MTD, up to nine additional patients could be treated. PK and determination of the phosphorylation of histone H3 in skin biopsies as PD assessments were performed. Results: Until December 2009, 52 patients had been treated with 5–140 mg BI 811283 at two investigational sites. The MTD was exceeded at 140 mg and will be established below this dose level. Reversible hematotoxicity was the main adverse event (AE); dose-limiting toxicity at 140 mg was neutropenia. Neutrophil count was shown to be dose dependent. Other AEs with a frequency of ≥5% and CTCAE grade ≥3 considered drug-related were neutropenia (n=9, 17.3%) and leukopenia (n=9, 17.3%). The mean number of courses was 3.0 across all dose groups in this schedule. 16 or more courses of treatment at this schedule were administered in two patients without evidence of accumulating toxicity. Stable disease as best response was reported in 29% of patients. Preliminary PK analysis showed near-linear PK; mean -------t½ was 11.9–26 hours. The PK profile appeared similar to the q3w profile. Exposure appeared to be related to patients' predose AGP levels. Results from PD assessment are pending. Conclusions: BI 811283 is a potent, selective Aurora B inhibitor with a favorable PK and safety profile. The MTD in the 4-week schedule (q2w) was exceeded at 140 mg; MTD evaluation is ongoing. Data from dose escalation, the expanded patient cohort and the q3w schedule will be analyzed in defining the optimal dose/schedule for BI 811283, taking PK and PD data into account. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Boehringer Ingelheim Boehringer Ingelheim
Abstract 12030: Trends in Blood Pressure Among Adults With Hypertension: United States, 2003-2012
Authors: Sung Sug (Sarah) Yoon, Qiuping Gu, Tatiana Nwankwo, Jacqueline Wright, Yuling Hong, Vicki Burt
Journal: Circulation (2014)

Objectives: To describe trends in the awareness, treatment and control of hypertension; mean blood pressure; and the classification of blood pressure among U.S. adults 2003-2012. Methods and Results: Using data from the National Health and Nutrition Examination Survey 2003-2012, a total of 9,255 adult participants aged 18 and older were identified as having hypertension, defined as measured blood pressure ≥ 140/90 mm Hg or taking prescription medication for hypertension. Awareness and treatment among hypertensive adults were ascertained via an interviewer administered questionnaire. Controlled hypertension among hypertensive adults was defined as systolic blood pressure &lt;140 mm Hg and diastolic blood pressure &lt; 90 mm Hg. Blood pressure was categorized as optimal blood pressure, prehypertension, stage I hypertension and stage II hypertension. Between 2003 and 2012, the percent of adults with controlled hypertension increased ( p -trend &lt;0.01). Hypertensive adults with optimal blood pressure and with prehypertension increased from 13% to 19% and 27% to 33%, respectively ( p - trend &lt; 0.01). Among hypertensive adults who were taking anti-hypertensive medication, uncontrolled hypertension decreased from 38% to 30% ( p -trend &lt;0.01). Similarly, a decrease in mean systolic blood pressure was observed ( p -trend &lt;0.01); however, mean diastolic blood pressure remained unchanged. Conclusion: The trend in the control of blood pressure has improved among hypertensive adults resulting in a higher percent with blood pressure at the optimal or prehypertension level and a lower percent in stage I and stage II hypertension. Overall, mean systolic blood pressure decreased as did the prevalence of uncontrolled hypertension among the treated hypertensive population.
Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
Authors: Farrah Mikhail Datko, Gabriella D'Andrea, Maura N. Dickler, Maria Theodoulou, Shari Beth Goldfarb, Diana Lake, Monica Nancy Fornier, Shanu Modi, Nancy T. Sklarin, Elizabeth Anne Comen, Julie Fasano, Devika Gajria, Pamela Drullinsky, Conleth G. Murphy, Angemael Syldor, Sujata Patil, Jennifer Liu, Sarat Chandarlapaty, Clifford Hudis, Chau T. Dang
Journal: Journal of Clinical Oncology (2012)

134 Background: Pertuzumab (P) is a monoclonal antibody which binds to extracellular domain II of HER2 distally from trastuzumab (H), disrupting HER2 dimerization and signaling. The CLEOPATRA phase III trial showed that HP + docetaxel in HER2+ MBC prolonged progression-free survival (PFS) compared to placebo + H + docetaxel. We report preliminary results of a phase II study to evaluate the safety and efficacy of weekly paclitaxel (T) with HP (THP). Methods: Patients (pts) with HER2+ MBC with 0-1 prior treatment (Rx) are eligible. Pts receive weekly (w) paclitaxel (80mg/m 2 ), q3w trastuzumab (loading dose 8mg/kg → 6mg/kg), and q3w pertuzumab (flat loading dose 840mg → flat dose 420mg). The primary endpoint is PFS at 6 months (mo). Secondary endpoints include response, safety (including cardiac events), and tolerability. Evaluable pts are those who have started study Rx and are assessed at 6 mo for PFS. Left ventricular ejection fraction (LVEF) is monitored by echocardiogram every 3 mo. Cardiac events are defined as symptomatic LV systolic dysfunction (LVSD), non-LVSD cardiac death, or probable cardiac death. Results: As of 5-1-12, 33 of the planned 69 pts were enrolled; 16 were evaluable at 6 mo. Of the 16 pts, G 3/4 toxicities included sepsis (1pt, 6%), cholecystitis (1pt, 6%), fatigue (1pt, 6%), skin ulceration (1pt, 6%) and cystic macular degeneration (1 pt with prior prolonged Rx with paclitaxel, 6%). G 1/2 toxicities included alopecia (16 pts, 100%), fatigue (15 pts, 94%), ALT/AST elevation (14 pts, 88%), neuropathy (14 pts, 88%), diarrhea (12 pts, 75%), rash (9 pts, 56%), nail changes (8 pts, 50%), nausea (7 pts, 44%), mucositis (7 pts, 44%), and dry skin (6 pts, 38%). Median LVEF was 63% at baseline, 60% at 3 mo and 58% at 6 mo. There were no cardiac events. At 6 mo, 12/16 pts (75%) were progression-free (2 CR, 7 PR and 3 SD); 4 pts progressed. Conclusions: Our single-center phase II study continues to accrue, with no significant diarrhea or signal of increased cardiac toxicity to date. If the estimate of activity is similar to results with docetaxel in CLEOPATRA, this will provide support for THP as an alternative option in this setting.
CD8+ T cell responses in metastatic melanoma patients receiving an adenovirally antigen engineered dendritic cell vaccine +/- IFN-α
Authors: Samuel Du, Patricia M Santos, Hussein Tawbi, Ahmad Tarhini, John M Kirkwood, Lisa H Butterfield
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Dendritic cells (DC), the primary antigen presenting cells and stimulators of naïve immune cells, are uniquely positioned to promote anti-tumor immunity. We developed a DC vaccine which expresses three full length melanoma antigens tyrosinase, MART-1, and MAGE-A6 engineered with
Interleukin-2-Dependent Allergen-Specific Tissue-Resident Memory Cells Drive Asthma
Authors: Brian D. Hondowicz, Dowon An, Jason M. Schenkel, Karen S. Kim, Holly R. Steach, Akshay T. Krishnamurty, Gladys J. Keitany, Esteban N. Garza, Kathryn A. Fraser, James J. Moon, William A. Altemeier, David Masopust, Marion Pepper
Journal: Immunity (2015)
Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency
Authors: Ying Dang, Gengxiang Jia, Jennie Choi, Hongming Ma, Edgar Anaya, Chunting Ye, Premlata Shankar, Haoquan Wu
Journal: Genome biology (2015)

Single-guide RNA (sgRNA) is one of the two key components of the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 genome-editing system. The current commonly used sgRNA structure has a shortened duplex compared with the native bacterial CRISPR RNA (crRNA)-transactivating crRNA (tracrRNA) duplex and contains a continuous sequence of thymines, which is the pause signal for RNA polymerase III and thus could potentially reduce transcription efficiency.Here, we systematically investigate the effect of these two elements on knockout efficiency and showed that modifying the sgRNA structure by extending the duplex length and mutating the fourth thymine of the continuous sequence of thymines to cytosine or guanine significantly, and sometimes dramatically, improves knockout efficiency in cells. In addition, the optimized sgRNA structure also significantly increases the efficiency of more challenging genome-editing procedures, such as gene deletion, which is important for inducing a loss of function in non-coding genes.By a systematic investigation of sgRNA structure we find that extending the duplex by approximately 5 bp combined with mutating the continuous sequence of thymines at position 4 to cytosine or guanine significantly increases gene knockout efficiency in CRISPR-Cas9-based genome editing experiments.
Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?
Authors: D Benedetti, E Tissino, C Caldana, M Dal Bo, R Bomben, D Marconi, S Ganghammer, F Zaja, G Pozzato, F Di Raimondo, T N Hartmann, G Del Poeta, A VanMeter, A Zucchetto, V Espina, L Liotta, V Gattei
Journal: Leukemia (2015)
Investigation of free amino acid, total phenolics, antioxidant activity and purine alkaloids to assess the health properties of non-Camellia tea
Authors: Wu Bi, Chunnian He, Yunyun Ma, Jie Shen, Linghua Harris Zhang, Yong Peng, Peigen Xiao
Journal: Acta Pharmaceutica Sinica B (2015)

To find novel functional beverages from folk teas, 33 species of frequently used non-Camellia tea (plants other than Camellia) were collected and compared with Camellia tea (green tea, pu-erh tea and black tea) for the first time. Data are reported here on the quantities of 20 free amino acids (FAAs) and three purine alkaloids (measured by UHPLC), total polyphenols (measured by Folin-Ciocalteu assay), and antioxidant activity (DPPH). The total amounts of FAAs in non-Camellia tea (0.62-18.99 mg/g) are generally less than that of Camellia tea (16.55-24.99 mg/g). However, for certain FAAs, the quantities were much higher in some non-Camellia teas, such as γ-aminobutyric acid in teas from Ampelopsis grossedentata, Isodon serra and Hibiscus sabdariffa. Interestingly, theanine was detected in tea from Potentilla fruticosa (1.16±0.81 mg/g). Furthermore, the content of polyphenols in teas from A. grossedentata, Acer tataricum subsp. ginnala are significantly higher than those from Camellia tea; teas from I. serra, Pistacia chinensis and A. tataricum subsp. ginnala have remarkable antioxidant activities similar to the activities from green tea (44.23 μg/mL). Purine alkaloids (caffeine, theobromine and theophylline) were not detected in non-Camellia teas. The investigation suggest some non-Camellia teas may be great functional natural products with potential for prevention of chronic diseases and aging, by providing with abundant polyphenols, antioxidants and specific FAAs.
The Nutritional and Social Environment-Related Effects of Breastfeeding on Intelligence
Authors: Fabian Kosse
Journal: JAMA Pediatrics (2015)

The Nutritional and Social Environment-Related Effects of Breastfeeding on IntelligenceWhile various studies document a positive association between duration of breastfeeding and the child's intelligence, there is an ongoing discussion about the mechanisms behind that association. 1,2 The usual approach to distinguish between nutritional and confounding environment-related effects is to control for observable environmental factors in the analysis.Varying availability and measures of control variables make comparisons across studies difficult and lead to different results concerning the partial correlation between duration of breastfeeding and intelligence. 1,2 This study provides a new empirical test of the purely nutritional effect of breastfeeding on the child's intelligence and does not rely on the availability of control variables.
Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)
Authors: L. Millon, R. Herbrecht, F. Grenouillet, F. Morio, A. Alanio, V. Letscher-Bru, S. Cassaing, T. Chouaki, C. Kauffmann-Lacroix, P. Poirier, D. Toubas, O. Augereau, S. Rocchi, D. Garcia-Hermoso, S. Bretagne, H. Dupont, J.P. Marolleau, A. Totet, C. Damiani, A. Berceanu, F. Larosa, J. Bonhomme, C. Chabrot, B. Bouteille, D. Boutoille, T. Gastinne, P. Peterlin, M. Gari Toussaint, D. Poisson, D. Briet, J. Buret, M. Legrand, B. Denis, E. Raffoux, A. Bergeron, A. Veinstein, C. Godet, Y. N'guyen, S. Diallo, M. Sabou, J. Denis, M.P. Ledoux, C. Recher, J. Ruiz, G. Desoubeaux, E. Bailly, E. Chachaty, F. Dromer, O. Lortholary, K. Sitbon, D. Hoinard
Journal: Clinical Microbiology and Infection (2015)